Targeting PPARα activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation.
Wang ZC, Li C, Zhang Z, Lu S, Liu YM, Qi P, Chen X, Wang YB, Feng WJ, Pan CL, Wang QX, Ji ZL, Yu Y, Piao MH, Chi GF, Ge PF.
Wang ZC, et al. Among authors: liu ym.
Acta Pharmacol Sin. 2025 Jun 11. doi: 10.1038/s41401-025-01600-z. Online ahead of print.
Acta Pharmacol Sin. 2025.
PMID: 40500345